Berlin Institute of Health at Charité (BIH) at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Berlin Institute of Health at Charité (BIH) brings 3 presentations to ESGCT 2026 in Hamburg. Its contributions cover engineered T cells for people after solid organ transplantation, including a GMP-compatible CRISPR platform that makes antiviral cells resistant to tacrolimus. A second strand uses targeted demethylation to induce and stabilise antigen-specific regulatory T cells.
| Organization | ESGCT 2026 Attendance |
|---|---|
Berlin Institute of Health at Charité (BIH) Berlin, Germany | |
Translational research institute within Charité, including a centre for regenerative therapies working on cell and gene therapy. | Talk Tue Oct 27 6:45pm–7:30pm A Pan-Viral GMP-compatible CRISPR–Cas9-based platform for Tacrolimus-resistant antiviral T-cell therapies after solid organ transplantation Cell therapies and CAR-TGene and epigenome editing Poster Wed Oct 28 1:30pm–3:30pm Targeted FOXP3-TSDR demethylation for de novo induction and functional stabilization of antigen-specific regulatory T cells Talk Thu Oct 29 9:10am–10:30am SESSION 7c: Accessibility of GT Manufacturing, CMC and access |
Instantly find 20 buyers from Berlin Institute of Health at Charité (BIH)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction